Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxol dose intensification and its clinical implications

G Sarosy1, E Reed

  • 1Medical Ovarian Cancer Section, National Cancer Institute, Bethesda, MD 20892.

Journal of the National Medical Association
|June 1, 1993
PubMed
Summary

Increasing the dosage intensity of Taxol (paclitaxel) significantly improves treatment response rates in ovarian cancer patients. This review highlights the importance of dose intensity for effective Taxol therapy in managing this malignancy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated assessment of the effects of PFOA exposure on hepatic transcriptome and lipid profiles in mice expressing human PPARα.

Toxicology and applied pharmacology·2025
Same author

A new mechanism for void-cascade interaction from nondestructive depth-resolved atomic-scale measurements of ion irradiation-induced defects in Fe.

Science advances·2020
Same author

Multi-level Determinants of Clinic Attendance and Antiretroviral Treatment Adherence Among Fishermen Living with HIV/AIDS in Communities on Lake Victoria, Uganda.

AIDS and behavior·2018
Same author

Challenges and solutions in the development of genomic biomarker panels: a systematic phased approach.

Current genomics·2012
Same author

Motherhood and HIV risk among female sex workers in Andhra Pradesh, India: the need to consider women's life contexts.

AIDS and behavior·2012
Same author

Quality of life assessments in advanced breast cancer: should there be more consistency?

European journal of cancer care·2012

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Background:

  • Taxol (paclitaxel) is a significant anticancer agent with demonstrated efficacy across various malignancies.
  • Notable activity has been observed in ovarian and breast cancers, as well as non-small cell lung cancer and melanoma.
  • Emerging research indicates a potential link between Taxol administration and patient response rates.

Purpose of the Study:

  • To review studies investigating the impact of Taxol dose intensity on treatment outcomes.
  • To evaluate the efficacy of increased milligram dosage per unit time (mg/m2/week) of Taxol in ovarian cancer patients.

Main Methods:

  • Review of existing clinical studies and research data.
  • Analysis of treatment protocols focusing on Taxol dosage and administration schedules.

Related Experiment Videos

  • Evaluation of response rates in patients with ovarian cancer based on varying Taxol dose intensities.

    • Main Results:

    • Studies suggest a marked increase in response rates for ovarian cancer patients when Taxol is administered at higher dose intensities (mg/m2/week).
    • The data indicates a strong correlation between escalated Taxol dosage per unit time and improved treatment efficacy.
    • This dose-response relationship appears particularly significant in the context of ovarian cancer treatment.

    Conclusions:

    • Taxol dose intensity is a critical factor in achieving optimal treatment responses in ovarian cancer.
    • Adjusting administration schedules to increase Taxol mg/m2/week may enhance therapeutic benefits.
    • Further research into dose optimization could improve Taxol's role in managing ovarian and other cancers.